Previous 10 | Next 10 |
2024-01-09 08:47:19 ET More on Perspective Therapeutics Perspective Therapeutics to divest brachytherapy business Seeking Alpha’s Quant Rating on Perspective Therapeutics Historical earnings data for Perspective Therapeutics Financial information for P...
2024-01-09 08:02:28 ET More on Lantheus Lantheus Stock: Looking To Add After SPLASH's Belly-Flop Lantheus: SPLASHdown, Navigating Waves In MCRPC Treatment William Blair downgrades Lantheus to market perform Lantheus, Point BioPharma drop amid results of SPLAS...
Option to license Perspective Therapeutics’ Pb212-VMT-α-NET asset Co-development rights for certain Pb212-based alpha therapies for prostate cancer Equity investment of up to 19.9% in Perspective Therapeutics Perspective Therapeutics intends to acquire Some...
Full year 2023 worldwide revenue expected to be in the range of $1.295 – 1.297 billion, a 38 - 39% increase over the prior year including a $15 million RELISTOR milestone achievement Full year 2023 PYLARIFY revenue expected to be in the range of $851 - 853 million, pending final ...
BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Mary Anne Hei...
2024-01-01 12:52:26 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Undoubtedly, 2023 was the year of AI on Wall Street. We saw many AI-related companies absolutely skyrocket last year, with semiconductor firms leading the charge. Their meteoric rise and contin...
2023-12-26 07:43:47 ET More on POINT Biopharma Global Why POINT Biopharma Global Is At Least A Hold On Disappointing Readout POINT Biopharma Global: Why The Market Believes That A Second Bidder May Emerge Eli Lilly POINTs Toward Radiopharmaceutical Ambitions ...
2023-12-20 08:30:00 ET Summary Point Biopharma and Lantheus Holdings released positive topline results for their radioligand therapy in patients with metastatic castration-resistant prostate cancer. The SPLASH trial met its primary endpoint, showing a progression-free survival ben...
2023-12-19 14:14:12 ET More on Lantheus Lantheus: SPLASHdown, Navigating Waves In MCRPC Treatment Lantheus Holdings: Huge Catalysts Ahead And Cheap Valuation Lantheus Holdings, Inc. (LNTH) Q3 2023 Earnings Call Transcript Lantheus, Point BioPharma drop amid r...
2023-12-18 23:16:26 ET Summary Lantheus stock dropped 26% post-SPLASH study, highlighting risks in mCRPC drug development and its strategic alliance with POINT Biopharma. SPLASH trial met primary goals but showed underwhelming overall survival data, affecting investor confidence a...
News, Short Squeeze, Breakout and More Instantly...
Lantheus Holdings Inc. Company Name:
LNTH Stock Symbol:
NASDAQ Market:
Lantheus Holdings Inc. Website:
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully ...
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second...
BEDFORD, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acqu...